Qilu Pharmaceutical Co., Ltd.

Zhenming An

Yingying Yang

Feifei Liu

Jinjin Jiang

Guijiang Wang

Shicong Liu

Daoyuan Li

Jiulin Wang

Yue Yu

Qingmin Wang

Gao Li

Shuyong Zhao

Yuxue Liu

Chuanlei Liu

Bo Xie

Yaning Wang

Huanlan Zheng

Peng Wan

Meijuan Zhang

Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.

Antibody against claudin 18A2 and use thereof

Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.

Composition comprising aflibercept and a variant thereof, and related methods and uses

Growing community of inventors

Shandong, China

Zhenming An